An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
Background. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs) were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison of the genomic and gene expression profiles of...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2014/282815 |
id |
doaj-e1a1c070c0f14343a3a2a549be22a4d4 |
---|---|
record_format |
Article |
spelling |
doaj-e1a1c070c0f14343a3a2a549be22a4d42020-11-24T20:42:52ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/282815282815An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent GlioblastomasJulien Laffaire0Anna Luisa Di Stefano1Olivier Chinot2Ahmed Idbaih3Jaime Gallego Perez-Larraya4Yannick Marie5Nadia Vintonenko6Blandine Boisselier7Patrizia Farina8Jean-Yves Delattre9Dominique Figarella-Branger10Jérôme Honnorat11Marc Sanson12François Ducray13Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAssistance Publique-Hôpitaux de Marseille, Service de Neuro-Oncologie, Centre Hospitalier Universitaire Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 05, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceAix-Marseille Université, Inserm, CRO2 UMR_S 911, 13385 Marseille, FranceANOCEF (Association des Neuro-Oncologues d’Expression Française (French Speaking NeuroOncologists’ Association)), FranceAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, Paris, FranceANOCEF (Association des Neuro-Oncologues d’Expression Française (French Speaking NeuroOncologists’ Association)), FranceBackground. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs) were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison of the genomic and gene expression profiles of the responders (n=12) and nonresponders (n=13) demonstrated only slight differences and could not identify any robust biomarkers associated with the response. In contrast, a significant association was observed between GBMs molecular subtypes and response rates. GBMs assigned to molecular subtype IGS-18 and to classical subtype had a lower response rate than those assigned to other subtypes. In an independent series of 33 patients, neither EGFR amplification nor CDKN2A deletion (which are frequent in IGS-18 and classical GBMs) was significantly associated with the response rate, suggesting that these two alterations are unlikely to explain the lower response rate of these GBMs molecular subtypes. Conclusion. Despite its limited sample size, the present study suggests that comparing the initial molecular profiles of responders and nonresponders might not be an effective strategy to identify biomarkers of the response to bevacizumab given at recurrence. Yet it suggests that the response rate might differ among GBMs molecular subtypes.http://dx.doi.org/10.1155/2014/282815 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julien Laffaire Anna Luisa Di Stefano Olivier Chinot Ahmed Idbaih Jaime Gallego Perez-Larraya Yannick Marie Nadia Vintonenko Blandine Boisselier Patrizia Farina Jean-Yves Delattre Dominique Figarella-Branger Jérôme Honnorat Marc Sanson François Ducray |
spellingShingle |
Julien Laffaire Anna Luisa Di Stefano Olivier Chinot Ahmed Idbaih Jaime Gallego Perez-Larraya Yannick Marie Nadia Vintonenko Blandine Boisselier Patrizia Farina Jean-Yves Delattre Dominique Figarella-Branger Jérôme Honnorat Marc Sanson François Ducray An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas BioMed Research International |
author_facet |
Julien Laffaire Anna Luisa Di Stefano Olivier Chinot Ahmed Idbaih Jaime Gallego Perez-Larraya Yannick Marie Nadia Vintonenko Blandine Boisselier Patrizia Farina Jean-Yves Delattre Dominique Figarella-Branger Jérôme Honnorat Marc Sanson François Ducray |
author_sort |
Julien Laffaire |
title |
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas |
title_short |
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas |
title_full |
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas |
title_fullStr |
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas |
title_full_unstemmed |
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas |
title_sort |
anocef genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2014-01-01 |
description |
Background. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs) were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison of the genomic and gene expression profiles of the responders (n=12) and nonresponders (n=13) demonstrated only slight differences and could not identify any robust biomarkers associated with the response. In contrast, a significant association was observed between GBMs molecular subtypes and response rates. GBMs assigned to molecular subtype IGS-18 and to classical subtype had a lower response rate than those assigned to other subtypes. In an independent series of 33 patients, neither EGFR amplification nor CDKN2A deletion (which are frequent in IGS-18 and classical GBMs) was significantly associated with the response rate, suggesting that these two alterations are unlikely to explain the lower response rate of these GBMs molecular subtypes. Conclusion. Despite its limited sample size, the present study suggests that comparing the initial molecular profiles of responders and nonresponders might not be an effective strategy to identify biomarkers of the response to bevacizumab given at recurrence. Yet it suggests that the response rate might differ among GBMs molecular subtypes. |
url |
http://dx.doi.org/10.1155/2014/282815 |
work_keys_str_mv |
AT julienlaffaire ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT annaluisadistefano ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT olivierchinot ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT ahmedidbaih ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jaimegallegoperezlarraya ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT yannickmarie ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT nadiavintonenko ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT blandineboisselier ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT patriziafarina ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jeanyvesdelattre ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT dominiquefigarellabranger ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jeromehonnorat ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT marcsanson ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT francoisducray ananocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT julienlaffaire anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT annaluisadistefano anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT olivierchinot anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT ahmedidbaih anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jaimegallegoperezlarraya anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT yannickmarie anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT nadiavintonenko anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT blandineboisselier anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT patriziafarina anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jeanyvesdelattre anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT dominiquefigarellabranger anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT jeromehonnorat anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT marcsanson anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas AT francoisducray anocefgenomicandtranscriptomicmicroarraystudyoftheresponsetoirinotecanandbevacizumabinrecurrentglioblastomas |
_version_ |
1716821527453761536 |